|
Volume 15, Issue 6 (November 2013) 15, 709–710; 10.1038/aja.2013.96
Castration-resistant prostate cancer: a strategy to enhance response to androgen deprivation
Yuri Stanevsky1, Alexander Tsivian1 and Matvey Tsivian2
1Department of Urologic Surgery, The E. Wolfson Medical Center, Holon and Sackler school of Medicine, Tel Aviv University, Tel Aviv 53000, Israel
2Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Correspondence: Dr M Tsivian, (matvey.tsivian@duke.edu)
29 July 2013
| Abstract |
|
A new research study evaluated the mechanisms of prostate cancer (PCa) resistance to androgen deprivation therapy (ADT) and progression to castrate-resistant disease. Using a coclinical approach, the investigators were able to identify key genetic determinants of ADT resistance, gain insight into the molecular pathways that play a key role in this transition and propose a potential management strategy to overcome ADT resistance in select cancers. This represents a step forward towards personalized medicine guided by specific molecular markers of prostate cancer enabling more effective therapies targeted towards altered metabolic pathways.
PDF |
PDF |
|
| |
| Browse: 2806 |
|
